Is NCT04848064 recruiting in Columbus, OH?

Yes, NCT04848064 is currently recruiting participants at its Columbus, OH location. This recurrent adult t-cell leukemia/lymphoma clinical trial is actively enrolling qualified participants.

Is participation in this Columbus clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Recurrent Adult T-Cell Leukemia/Lymphoma Clinical Trial in Columbus, OH

Q: How do I join the recurrent adult t-cell leukemia/lymphoma clinical trial in Columbus?

To join this clinical trial in Columbus, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Recurrent Adult T-Cell Leukemia/Lymphoma Study in Columbus

This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.

Sponsor: John Reneau

Who Can Participate

Inclusion Criteria

Able to understand and voluntarily sign an informed consent form

Age \>= 18 years at the time of signing the informed consent form

Able to adhere to the study visit schedule and other protocol requirements

Biopsy-proven, measurable, stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy

Note: extracorporeal photopheresis will be considered a systemic therapy for this study

Patients with large cell transformation of cutaneous T cell lymphoma are eligible

Patients with adult T-cell leukemia/lymphoma (ATLL) of any stage and any subtypes. Patient must have had at least one standard chemotherapy and measurable disease at the time of enrollment

Patients who relapsed after autologous or allogeneic stem cell transplant are eligible

All cancer therapy, including radiation, topical steroid, and chemotherapy must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study. The only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (\> 60 days) without change. These patients may continue use of either systemic steroids (equivalent to \< 10 mg per day of prednisone) or topical steroids if the frequency and dosage steroids has not changed for 21 days prior to the study. These participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be tapered or discontinued. Patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (ie, steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents

Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1 at study entry

Absolute neutrophil count \>= 1000/mm\^3

Platelet count \>= 50,000/mm\^3

Total bilirubin =\< 2 x upper limit of normal (ULN)

Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and Alanine Aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 3 x ULN

AST (SGOT) and ALT (SGPT) =\< 5 x ULN in patients with documented hepatic involvement by lymphoma

Calculated creatinine clearance \>= 50 ml/min (by the Crockroft-Gault equation)

Disease free of prior malignancies for \>= 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible. Patients with B-cell lymphomas treated with curative intent, and in remission for at least 2 years, may be in included (after discussion with principal investigator \[PI\])

Negative serum pregnancy test at the time of enrollment for females of childbearing potential. Women who can get pregnant and men with partners who can become pregnant will be asked to practice a highly effective method of birth control while participating in the study that is considered medically acceptable by the study doctor.

Life expectancy \>= 90 days

Exclusion Criteria

Investigational therapies in the 2 weeks prior to beginning treatment on trial

Patients with active central nervous system (CNS) involvement with lymphoma

Patients with known human immunodeficiency virus (HIV) infection with CD4 \< 350

Patients who had solid organ transplants

Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection based on positive PCR. Patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing

Present or history of progressive multifocal leukoencephalopathy (PML)

Active grade II-IV acute or extensive chronic graft versus (vs.) host disease (GVHD)

Patients may take steroids at any dose for disease control up to 24 hours prior to study enrollment. Steroids must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study, per inclusion criteria above. Topical steroids are allowed for CTCL patients

Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety

A cardiovascular disability status of New York Heart Association class \>= 2

History of severe allergic reactions to humanized monoclonal antibodies

History of other malignancy that could affect compliance with the protocol or interpretation of results. Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible

Known hypersensitivity to any of the study drugs or analogs

Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy

Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis

Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment

Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis

Receiving immunosuppressive therapy

Prior therapy with mogamulizumab unless stopped previously for reasons other than progression or toxicity.

Pregnant or lactating, or intending to become pregnant during the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Columbus?

Yes, this clinical trial (NCT04848064) has an active research site in Columbus, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Adult T-Cell Leukemia/Lymphoma Treatment Options in Columbus, OH

If you're searching for recurrent adult t-cell leukemia/lymphoma treatment options in Columbus, OH, this clinical trial (NCT04848064) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Columbus research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced recurrent adult t-cell leukemia/lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent adult t-cell leukemia/lymphoma clinical trials near you to find additional studies recruiting in your area.

Recurrent Adult T-Cell Leukemia/Lymphoma Clinical Trial in Columbus, OH

Expert Care in Columbus

IRB Approved

No-Cost Care

Apply for This Columbus Location

Why Participate?

Simple Process